Didn't find what you were looking for?

Discover Actorius' journey. Learn how our innovation-driven, impact-obsessed start-up is revolutionizing early cancer detection. Our story so far An innovation-driven organisation 11000+ Patients Served Globally 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. Filtering Cancer. Fighting Metastasis. Know More

Explore our Actorius Innovation's Terms & Conditions. Understand your rights and obligations with our comprehensive Terms & Conditions. Terms & Conditions Date Updated: 03 March 2026 Welcome to the official website of Actorius Innovations & Research Co. (“Company,” “we,” “us,” or “our”), accessible at [https://actorius.com ] (the “Website”). By accessing or using this Website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing, browsing, or using this Website, you confirm that you have read, understood, and agreed to these Terms and our Privacy Policy. 2. Use of the Website The content on this Website is provided for general informational and educational purposes only and may be updated without notice. You agree to: Use the Website only for lawful purposes Not misuse, disrupt, or attempt to gain unauthorized access Not infringe upon the rights of others Important: This Website does not provide medical advice. Any healthcare-related content, including information about therapeutic solutions such as OncoMetstat, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for medical decisions. 3. Intellectual Property Rights All content on this Website—including text, graphics, logos, images, software, and design—is owned by Actorius Innovations & Research Pvt. Ltd. or its licensors and is protected under U.S. and international intellectual property laws. You may not: Copy, reproduce, or distribute content Modify or create derivative works Use content for commercial purposes Without prior written permission. 4. Third-Party Links This Website may include links to third-party websites for convenience. We: Do not control or endorse third-party content Are not responsible for their privacy practices or terms Disclaim liability for any damages resulting from third-party use 5. Disclaimer of Warranties This Website is provided on an “as is” and “as available” basis. To the fullest extent permitted under applicable U.S. law, we disclaim: All warranties (express or implied), including merchantability and fitness for a particular purpose Any guarantee that the Website will be uninterrupted, secure, or error-free 6. Limitation of Liability To the maximum extent permitted by law, Actorius Innovations & Research Pvt. Ltd. shall not be liable for: Indirect, incidental, consequential, or punitive damages Loss of profits, data, or business opportunities Damages arising from use or inability to use the Website Some U.S. states do not allow certain limitations, so parts of this section may not apply to you. 7. Indemnification You agree to indemnify and hold harmless Actorius Innovations & Research Pvt. Ltd., its affiliates, officers, employees, and partners from any claims, damages, or expenses arising from: Your use of the Website Your violation of these Terms Your infringement of any third-party rights 8. Healthcare & Diagnostic Services Disclaimer Services referenced on this Website (including diagnostics, research, or analytics): May be subject to additional agreements and regulatory requirements Are not available in all jurisdictions May require physician involvement or authorization Where applicable, services handling health data may be governed by the Health Insurance Portability and Accountability Act (HIPAA) and related regulations. 9. Services, Payments, Refunds, and Cancellations Where services are offered: Terms will be specified at the time of engagement Due to the scientific and diagnostic nature of services, refunds may be limited or unavailable once processing begins Cancellation requests must be submitted in writing and are evaluated case-by-case 10. Privacy Your use of the Website is also governed by our Privacy Policy, which outlines how we collect and use personal data, including rights under laws such as: U.S. state privacy laws (e.g., CCPA/CPRA) HIPAA (where applicable) 11. Governing Law and Jurisdiction These Terms shall be governed by the laws of the United States and the State of [Insert State, e.g., Delaware or California], without regard to conflict of law principles. You agree that any disputes shall be resolved in the courts located in: [California, USA] However, if you access the Website from outside the U.S., you are responsible for compliance with local laws. 12. International Users This Website is operated from the United States but may be accessed globally. By using the Website, you acknowledge that: Your data may be transferred to and processed in the United States U.S. data protection laws may differ from those in your jurisdiction 13. Modifications to Terms We may update these Terms at any time. Changes become effective immediately upon posting. Continued use of the Website constitutes acceptance of the updated Terms. 14. Termination We reserve the right to suspend or terminate access to the Website at our discretion, without notice, for conduct that violates these Terms or applicable laws. 15. Contact Information If you have any questions regarding these Terms: Actorius Innovations & Research Co. Website: https://actorius.com Contact Page: https://actorius.com/contact Email: info@actorius.com

Get in touch with us. We'd love to hear from you! Visit us for frequently asked questions and more information. Contact us First name* Last name* Email* Phone What are you looking for?* Book a demo Event enquiry Press or Media Enquiry Other Message* Submit Terms & Conditions | Privacy Policy We'd love to hear from you Whether it’s research, technology, or partnership opportunities, we’re here to explore what’s next—together. Write to us Our Address Visit Us Here’s where you can reach us in person. We look forward to welcoming you. US office 11842, Churchill Way, Porter Ranch, CA 91326 US Lab Pasadena Bio Collaborative Incubator, 2265 E Foothill Blvd, Pasadena, CA 91107 FAQS Frequently asked questions Answers to commonly asked questions about Actorius and our offerings. What does Actorius Innovations & Research do? Actorius focuses on advancing precision oncology through innovative research, diagnostics, and technology platforms. Our work is centered on understanding cancer biology in depth and translating insights into actionable outcomes. Who can reach out to Actorius? Researchers, clinicians, healthcare partners, institutions, and potential collaborators are welcome to contact us. We also engage with industry partners and organizations interested in advancing cancer diagnostics and care. How long does it take to receive a response after submitting the contact form? We typically respond within 1–2 business days. Queries that require technical or scientific review may take slightly longer, and we appreciate your patience. Can I request collaborations or partnerships through the contact form? Yes. The contact form can be used to initiate discussions around research collaborations, partnerships, or technology integrations. Please include relevant details so we can route your request appropriately. Where can I find more information about your services or products? Detailed information about our platforms, research focus, and offerings is available throughout the website. If you have a specific question not addressed online, feel free to contact us directly. Know More

Actorius Innovations and Research delivers regulatory-aligned cancer research solutions, enabling early detection, accurate monitoring, and impactful clinical decision support. From cell to certainty. Transforming deep biological insight into precise, actionable outcomes—so decisions are made earlier, clearer, and with confidence. Know More OncoMetastat® OncoMetastat® is an extracorporeal blood-processing platform engineered to selectively capture and deplete circulating tumor cells — designed to delay cancer metastasis in early stage cancers. Book a demo About We are in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. Trusted by: 11000+ Patients Served Globally 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Why choose us? Our approach is grounded in rigorous research, advanced platforms, and a commitment to meaningful outcomes. Patented Techologies Proprietary innovations designed to deliver precision, reliability, and real-world impact. Regulatory Approved Regulatory-approved solutions built to meet the highest standards of safety, compliance, and clinical integrity. Our Publications More than 100+ publications in ASCO, AACR, ESMO, ISLB, etc Read our publications Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. View all updates Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. March 17, 2026 Read More Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers March 17, 2026 Read More Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions March 17, 2026 Read More Actorius in Action Stay updated with our latest events, scientific discussions, collaborations, and milestones that continue to shape the future of cancer research and innovation. View all events Events AACR 2026 Highlights | April 17-22 | San Diego, California April 23, 2026 Read More Events Meeting with our KOLs February 20, 2026 Read More Events ISLB 2025 | 1-3 November 2025 November 3, 2025 Read More © Copyright Actorius Innovations and Research FAQS Frequently asked questions Answers to commonly asked questions about Actorius and our offerings. What makes Actorius different from conventional diagnostics companies? Actorius focuses on understanding cancer at the cellular level and translating that insight into precise, actionable outcomes. Our platforms are designed to look deeper, act earlier, and support more confident decisions. Who are Actorius’ solutions designed for? Our solutions are built for clinicians, researchers, healthcare partners, and institutions seeking advanced tools for cancer detection, analysis, and monitoring. How does Actorius approach precision oncology? We combine advanced biomaterials, biological insight, and data-driven analysis to study cancer behavior in detail—enabling earlier detection and more targeted intervention. Are Actorius’ technologies research-only or clinically applicable? Our work spans both research and translational applications. Some solutions are designed for research use, while others are developed with clinical deployment in mind, subject to regulatory requirements. How can I stay updated on Actorius’ work and developments? You can explore our latest blogs, newsletters, press releases, case studies, and events in the Resources section to stay informed about our progress and insights. Know More

Explore career opportunities at Actorius Innovations. Join us to innovate with intent and make a difference in patient lives. Careers Join us to be a part of our Journey Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Culture For us, at Actorius, commitment to team work comes first. We have a flat hierarchy. We believe that it takes all sorts to make a formidable team. That’s why we are, at times, open to welcoming passionate and driven people to be a part of our growing team. Team Building We are open to welcoming passionate and driven people to be a part of our growing team. We hold off-sites and affiliation events to bring together members of the team. We take pride in investing in individualised talent development programme and mentoring. Our People Driven by People, Defined by Purpose. Whether you’re an experienced professional or a recent graduate, working with Actorius could be an enriching experience and rewarding next step in your career. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. 50+ and counting We’re looking for dynamic thinkers and doers to help us make a difference to patient lives. Apply Now Jobs Current Job Openings Current openings at Actorius Innovations and Research Didn't find any relevant openings? You think you are driven by a vision to positively changes the lives of cancer patients? or you have a passion for research, fill in the following form. if we have a position that we think you're suitable for, we'll reach out to you. Apply Proactively

Discover our dynamic leadership team at Actorius Innovations. Join our leadership team to drive innovation and growth today! Our Dynamic Leadership Team Meet the team and learn about our mission. Dr. Jayant Khandare Cofounder, MD & CSO Aravindan Vasudevan Cofounder & Director Rick Kamble Cofounder & Director Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Explore our Privacy Policy. Learn how your data is protected and securely managed with our Privacy Policy. Privacy Policy Date Updated: 18 March 2026 Actorius Innovations and Research Co. (“we,” “us,” or “our”) is committed to protecting your privacy. This Privacy Policy explains how we collect, use, disclose, and safeguard your personal information when you access or use our website at [https://www.actorius.com ] (“Site”). This policy is designed to comply with applicable U.S. privacy laws, including the California Consumer Privacy Act (CCPA) , as amended by the California Privacy Rights Act (CPRA) , and other relevant federal and state regulations. 1. Information We Collect We may collect the following categories of personal information: a. Personal Information Information that identifies, relates to, or could reasonably be linked to you, including: Full name Email address Phone number (optional) Organization or company name (optional) Professional details you choose to share Any other information voluntarily submitted via forms or inquiries b. Automatically Collected Information (Usage Data) When you use our Site, we may automatically collect: IP address Browser type and version Device type and operating system Pages visited and time spent Referring and exit URLs Device identifiers Approximate geolocation (based on IP) 2. How We Use Your Information We use collected information to: Operate, maintain, and improve our Site Personalize your experience Analyze user behavior and site performance Respond to inquiries and provide support Send communications (only with your consent where required) Ensure security and prevent fraud Comply with legal obligations We will not use your personal information for materially different purposes without notice. 3. Disclosure of Information We do not sell personal information. We may disclose your information in the following situations: To service providers (e.g., hosting, analytics, CRM tools) under contractual obligations To comply with legal requirements (court orders, subpoenas, regulatory requests) To protect rights, property, or safety of our company, users, or others In connection with a business transaction (e.g., merger, acquisition, asset sale) 4. Cookies and Tracking Technologies We use cookies and similar technologies to: Remember user preferences Analyze website traffic Improve functionality Deliver relevant content and marketing (where permitted) Depending on your location (e.g., California), you may have the right to opt out of certain tracking technologies. You can manage cookies through your browser settings. 5. Your Privacy Rights If you are a resident of certain U.S. states (such as California), you may have the following rights: Right to Know – Request details about personal data collected and used Right to Access – Request a copy of your personal data Right to Delete – Request deletion of your personal data Right to Correct – Request correction of inaccurate data Right to Opt-Out – Opt out of sale or sharing of personal data (if applicable) Right to Non-Discrimination – You will not be discriminated against for exercising your rights To exercise your rights, please contact us using the details below. We may need to verify your identity before processing requests. 6. Data Retention We retain personal information only as long as necessary to: Fulfill the purposes outlined in this policy Comply with legal obligations Resolve disputes and enforce agreements 7. Data Security We implement reasonable administrative, technical, and physical safeguards to protect your personal information. However, no system is completely secure, and we cannot guarantee absolute security. 8. Children’s Privacy Our Site is not intended for individuals under the age of 13. We do not knowingly collect personal information from children. If we become aware of such data collection, we will delete it promptly in accordance with the Children’s Online Privacy Protection Act (COPPA). 9. Third-Party Links Our Site may contain links to third-party websites. We are not responsible for their privacy practices. We encourage you to review their policies before providing any information. 10. Changes to This Privacy Policy We may update this Privacy Policy from time to time. Updates will be posted on this page with a revised “Last Updated” date. 11. Contact Us If you have any questions or wish to exercise your privacy rights, please contact us: Website: https://www.actorius.com/contact Email: info@actorius.com

Rick Kamble Cofounder & Director Actorius Innovations & Research Co. Rick Kamble Cofounder & Director LinkedIn Qualification Master of Business Administration University of Phoenix, US Bachelor of Engineering Nagpur University, India Professional Summary Rick is an early investor in Actorius Innovations and Research (AIR) and chairman of the board. He is a serial entrepreneur based our of Los Angeles, US with expertise in Healthcare and Information Technology solutions. Rick is also the CEO and President of HealthNspire solutions, a HealthCare Technology solution provider focused on managed care software solutions. He is also the co-founder and CTO of Mediccio, a company dedicated to provide healthcare billing solutions using NLP. In the past, Rick has served as Senior VP of Product Strategies at AssistMed, a company dedicated to the application of Healthcare IT solutions. He has held leadership positions at Lakeside Medical Group, Jacobs Engineering, Farmers Insurance, L.A. CARE Health Plan, Cardinal Health, Countrywide Home Lo Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Aravindan Vasudevan Cofounder & Director Actorius Innovations & Research Co. Aravindan Vasudevan Cofounder & Director LinkedIn Qualification Bachelor of Science (Chemistry) University of Mumbai | 2000 Master of Science (Chemistry) University of Mumbai | 2002 Certificate in Business Studies (Marketing) UCLA Extension | 2012 Certified Medical Device Professional (CMDP) British Standards Institute | 2017 IRCA Certified ISO 13485:2016 Lead Auditor British Standards Institute | 2019 Have successfully created & filed multiple regulatory dossiers under Medical Device Regulations, 2017 with CDSCO, GoI. Implemented ISO 13485:2016 Quality Management System for medical device manufacturing. 20+ years comibined work experience in medical devices and pharmaceuticals. Professional Summary Aravindan Vasudevan is the Co-founder and Chief Executive Officer of Actorius Innovations and Research Pvt. Ltd. , a biotechnology and diagnostics company focused on advancing cancer detection and precision oncology technologies. With more than two decades of experience spanning pharmaceuticals, medical devices, and cancer diagnostics, he has played a pivotal role in translating complex scientific innovations into clinically relevant and commercially viable healthcare solutions. At Actorius, Aravindan was part of the core team that developed OncoDiscover , a pioneering liquid biopsy technology and India’s first indigenously developed DCGI-approved in vitro diagnostic (IVD) platform for the detection and analysis of circulating tumor cells (CTCs). This technology represents a significant step forward in non-invasive cancer diagnostics, enabling clinicians to monitor disease progression and personalize treatment strategies through advanced blood-based testing. Aravindan’s professional journey encompasses extensive experience in the pharmaceutical and medical device industries, including roles in manufacturing research and development, drug discovery, and technology commercialization . His expertise lies in building strategic pathways that enable the successful transition of scientific technologies from the research laboratory to real-world clinical and market applications. Over the years, he has contributed to the development of operational frameworks, regulatory strategies, and quality systems that support innovation-driven healthcare products. In addition to his leadership role at Actorius, Aravindan is associated with multiple ventures and collaborative initiatives aimed at advancing technologies in cancer diagnostics, cancer genomics, and novel drug delivery systems . His work focuses on integrating research, regulatory compliance, and market readiness to accelerate the adoption of next-generation biomedical technologies. Aravindan has significant experience navigating India’s regulatory landscape for medical devices. He has successfully developed and filed multiple regulatory dossiers under the Medical Device Rules, 2017 with the Central Drugs Standard Control Organization (CDSCO), Government of India , contributing to the regulatory approval and commercialization of innovative diagnostic technologies. He has also led the implementation of ISO 13485:2016 Quality Management Systems for medical device manufacturing, ensuring compliance with global quality standards. Beyond regulatory and commercialization expertise, Aravindan is an IRCA Certified ISO 13485:2016 Lead Auditor from the British Standards Institute (BSI) and a Certified Medical Device Professional (CMDP) . His professional training and certifications reflect a deep understanding of quality systems, regulatory frameworks, and global medical device standards. Aravindan holds both his Bachelor of Science and Master of Science degrees in Chemistry from the University of Mumbai . He further expanded his business and strategic management capabilities through a Certificate in Business Studies (Marketing) from UCLA Extension . In recognition of his entrepreneurial potential and contributions to innovation, he was also selected to participate in the Cornell Maha 60 Accelerator Program , a long-term initiative by Cornell University in partnership with the Department of Industries, Government of Maharashtra, designed to support high-impact technology entrepreneurs. With over 20 years of combined experience in pharmaceuticals and medical devices , Aravindan continues to drive innovation in oncology diagnostics, focusing on technologies that enable early detection, precision treatment decisions, and improved outcomes for cancer patients. Through his leadership at Actorius, he remains committed to advancing accessible, indigenous healthcare technologies that address critical challenges in cancer care. Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Dr. Jayant Khandare Cofounder, MD & CSO Actorius Innovations & Research Co. Dr. Jayant Khandare Cofounder, MD & CSO LinkedIn Qualification Master of Pharmacy (M. Pharm.) University of Mumbai | 1995 Ph.D. (Chemical Engineering) National Chemical Laboratory (NCL), Pune | 2003 Alexander von Humboldt (AvH) Experienced Researcher. Humboldt Foundation, Germany | 2008 Fellow of Royal Society of Chemistry (FRSC). Royal Society of Chemistry, UK | 2014 25+ US Patents, 100+ Peer Reviewed Scientific Articles Postdoctoral stints at Wayne State University (USA), Rutgers University (USA) and Freie Universität Berlin (Germany) in the area of targeted drug delivery for cancer. Research interests at the interface of macromolecular chemistry, biopolymer sciences, cancer biology, and cellular imaging. Professional Summary Dr. Jayant J. Khandare is a globally recognized cancer innovator and entrepreneur with more than two decades of experience at the intersection of chemical engineering, biomaterials, cancer biology, and translational oncology . He is the scientific architect behind multiple breakthrough platforms spanning cancer diagnostics, circulating tumor cell (CTC) technologies, and therapeutic intervention systems , many of which have progressed from concept to clinical and commercial validation. Dr. Khandare has authored over 150+ peer-reviewed scientific publications and is a named inventor on 25+ U.S. patents , reflecting a sustained track record of converting deep science into protectable, scalable intellectual property. His innovations form the foundation of several clinically relevant oncology platforms, including OncoDiscover® (CTC detection and enumeration) and OncoMetastat® (extracorporeal CTC filtration for metastasis mitigation) —technologies designed to address the most critical unmet need in cancer: the prevention and control of metastasis . Internationally trained, Dr. Khandare has held advanced research appointments in the United States and Germany , including postdoctoral work at Wayne State University , Rutgers University , and Freie Universität Berlin , with a strong focus on targeted drug delivery, macromolecular therapeutics, and cancer cell–material interactions . He is an Alexander von Humboldt Foundation Experienced Researcher and a Fellow of the Royal Society of Chemistry (UK) , honors reserved for scientists with sustained international impact. As a scientific founder and operator, Dr. Khandare brings a rare combination of visionary platform thinking and execution discipline . He has successfully built technologies across the full innovation lifecycle—from fundamental materials science and device engineering to translational studies, regulatory pathways, and clinical adoption . Under his leadership, Actorius’ platforms have generated extensive clinical evidence, international publications (ASCO, AACR, ESMO, ISLB), and a growing global IP estate. Dr. Khandare’s entrepreneurial mission is clear and consistent: to create first-in-class technologies that redefine how cancer is detected, monitored, and treated , with a particular focus on systemic disease biology rather than organ-limited paradigms. His work positions Actorius at the forefront of a new category in oncology—interventional cancer diagnostics and therapeutics . Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Explore the latest resources from Actorius, a leading Oncology focused biotech company. Discover cutting-edge insights and innovations today! Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Patents Publications Events Press Release Expert Insights April 23, 2026 Events AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Read More March 17, 2026 Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More March 17, 2026 Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More March 17, 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More March 17, 2026 Publications ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More March 17, 2026 Publications AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More March 17, 2026 Publications ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More March 17, 2026 Publications AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More March 17, 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More March 17, 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More March 14, 2026 Press Release Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More March 7, 2026 Publications AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More February 20, 2026 Events Meeting with our KOLs Our team meeting with oncology KOLs from the US and Europe. Read More February 5, 2026 Press Release Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More January 27, 2026 Publications Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More November 3, 2025 Publications PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More November 3, 2025 Publications Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More November 3, 2025 Publications Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More November 3, 2025 Publications Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More November 3, 2025 Events ISLB 2025 | 1-3 November 2025 Actorius ISLB 2025 | 1-3 November 2025 Read More October 20, 2025 Patents Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More October 17, 2025 Publications Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Read More October 17, 2025 Events ESMO 2025 | 17–21 October 2025 Actorius at ESMO 2025 Read More September 16, 2025 Publications PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Read More September 16, 2025 Publications Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. Read More June 3, 2025 Publications PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Read More June 3, 2025 Publications Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Read More June 3, 2025 Publications Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Read More June 3, 2025 Publications Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. Read More June 3, 2025 Publications Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Read More May 9, 2025 Publications Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Read More May 9, 2025 Events ISMRC 2025 | 7-9 May, 2025 Actorius at ISMRC 2025 Read More March 14, 2025 Publications Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Read More November 25, 2024 Publications ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Read More November 25, 2024 Publications ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression. Read More November 25, 2024 Publications ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. Read More September 17, 2024 Publications ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer. Read More July 15, 2024 Publications Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Read More June 29, 2024 Publications Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. Read More June 4, 2024 Publications ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. Read More June 3, 2024 Publications ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. Read More June 3, 2024 Publications ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Read More June 3, 2024 Publications ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Read More June 3, 2024 Publications ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Read More April 11, 2024 Press Release Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Read More April 10, 2024 Publications AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Read More April 10, 2024 Publications AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Read More April 4, 2024 Publications Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Read More October 24, 2023 Publications ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Read More September 20, 2023 Publications Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. Read More July 20, 2023 Publications Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). Read More June 6, 2023 Publications ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Read More June 6, 2023 Publications ASCO 2023: Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. A trial found CTCs in 60% of early-stage breast cancer patients, notably all HER2-positive cases, linking them to tumor grade. Send the next! Read More April 19, 2023 Publications AACR 2023: Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients. CTC analysis in 134 patients successfully detected PD-L1, HER2, and EGFR, proving its value as a real-time guide for targeted therapies. Read More April 11, 2023 Publications Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. Read More March 6, 2023 Press Release Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Read More February 28, 2023 Expert Insights TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. Read More February 13, 2023 Patents Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More January 15, 2023 Publications AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Read More August 9, 20222 Expert Insights OncoDiscover Available in India | Dr. Jayant Khandare OncoDiscover Available in India | Dr. Jayant Khandare Read More August 28, 2022 Expert Insights Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. Read More August 9, 2022 Expert Insights OncoDiscover Lab Walkthrough OncoDiscover Lab Walkthrough Read More August 9, 2022 Expert Insights Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care. Read More August 9, 2022 Press Release Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Read More August 9, 2022 Expert Insights Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. Read More July 1, 2022 Publications Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Read More June 7, 2022 Publications ASCO 2022: CTCs as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers. Read More June 7, 2022 Publications ASCO 2022: Machine learning (ML)–enabled, circulating tumor cell–based classification of patients for non-prerequisite adjuvant therapy. An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients. Read More June 7, 2022 Publications ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. Read More June 7, 2022 Publications ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes. A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response. Read More June 7, 2022 Publications ASCO 2022: Correlation of circulating tumor cells as a positive interventional biomarker in cancer patients Ayurveda therapy significantly reduced CTC counts and improved quality of life in a study of 72 patients across 17 cancer types. Read More April 27, 2022 Publications Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Read More February 18, 2022 Publications Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. Read More October 9, 2021 Publications ESMO 2021: Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs) Study shows significant CK18 expression variance across different cancer cell lines and CTCs, highlighting the need for regulated enumeration tools. Read More June 8, 2021 Publications ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection. Read More April 22, 2021 Patents Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More December 18, 2020 Publications Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Read More October 10, 2020 Publications Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Read More August 11, 2020 Expert Insights OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. Read More July 15, 2020 Publications ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Read More April 23, 2020 Press Release Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read More March 15, 2020 Publications ASCO 2020: Correlation of CTCs with disease progression in Indian oral cancer patients. In 230 OSCC patients, CTC counts correlated with cancer stage and aggressive features, proving CTCs are a reliable marker for disease stratification. Read More February 26, 2020 Patents Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More August 24, 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More August 24, 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More August 24, 2019 Press Release Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... Read More June 4, 2019 Publications ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Read More February 11, 2018 Publications Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Read More January 17, 2018 Publications Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. Read More January 17, 2017 Publications Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Read More April 17, 2015 Publications Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. Read More April 13, 2015 Publications Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. Read More First Prev 1 Page 1 Next Last

CTC counts correlate with nodal stage and aggressive features in Indian HNC patients. Publications March 7, 2026 AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Objectives To establish a rapid, highly specific, efficient, sensitive, and affordable CTC enumeration liquid biopsy technology and to validate its efficacy to isolate CTCs disseminating from epithelial tumors of the HNC subpopulation in India. Furthermore, the study aimed to investigate the correlation of CTC distribution from peripheral blood with respect to various clinicopathologic factors in these patients. Materials and Methods A cross-sectional study was conducted using peripheral blood from 350 enrolled HNC patients. CTCs were isolated using DCGI (India) approved technology that exploits EpCAM-based immunomagnetic separation. EpCAM+ tumor cells were isolated from only 1.5 ml of blood and critically assayed for cytokeratin 18 (CK18) expression. These cells were quantified using fluorescence imaging to obtain a threshold to further minimize nonspecific and false-positive enumeration. CTC enumeration was subsequently subjected to statistical correlation with various clinical and pathologic parameters. Results CTCs were detected in all HNC patients across various subsites. There was a minimum threshold of at least 12 CTCs in early oral cancer patients according to their clinicopathologic signatures. Compared to early oral cancer patients, advanced nodal patients showed a 40% escalation in CTC count, while an increase of up to 80% was observed when associated with aggressive features such as lymphovascular emboli (LVE) and extranodal extensions. Notably, laryngopharyngeal primary cases had the highest mean CTC count of 33 in 1.5 ml of blood. Conversely, patients with advanced disease had higher CTC counts, and this was staggered in comparison with nearly—but not all—clinical features. Remarkably, a higher clinical N (nodal) stage statistically correlated with increased CTC counts. A marked increase in CTCs was also seen in tumors that showed lymphovascular emboli on histopathology and extranodal extension. The CTC counts were independent of parameters such as age, sex, T stage, perineural invasion, bone involvement, or skin involvement. There was a notable trend toward reduced CTC counts after chemotherapy; however, it was not statistically significant. Conclusion This rapid and efficient CTC platform has been clinically validated for use in Indian HNC phenotypes. This is the first comprehensive study to show a staggering positive correlation between CTCs and various clinicopathologic factors, encompassing the largest number of oral cancer patients across the entire spectrum of HNSCC—the most common cancer in India. High CTC counts among HNC patients could possibly be one of the reasons for dismal outcomes, and further studies correlating CTCs with patient survival in HNC are warranted. However, this study strongly implicates the prospective utility of CTCs as a tumor marker in establishing clinical staging for HNC patients. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe